Strain Elastography as a Valuable Diagnosis Tool in Intermediate Cytology (Bethesda III) Thyroid Nodules.
Bethesda III category
cancer risk
modified TI-RADS
strain elastography
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
13 Sep 2019
13 Sep 2019
Historique:
received:
27
07
2019
revised:
10
09
2019
accepted:
12
09
2019
entrez:
22
9
2019
pubmed:
22
9
2019
medline:
22
9
2019
Statut:
epublish
Résumé
Fine needle aspiration (FNA) is considered the gold standard in the diagnostic of thyroid nodules. Using the recommended BETHESDA reporting system, up to 20% of results are classified as intermediate cytology. As there is no consensus whether ultrasound evaluation, lobectomy or surgery is the best treatment option, intermediate cytology results are considered a grey zone of the FNA. The main aim of our study was to evaluate the performance of combined advanced ultrasound techniques in the process of diagnosis and evaluation of the intermediate cytology cases after FNA. We evaluated 54 consecutive cases with intermediate cytology on FNA, using conventional B-mode ultrasound (2B), and strain elastography, using a linear multifrequency 6-13 MHz linear probe (Hitachi Prerius Machine, Hitachi Inc, Japan). All nodules were classified with our Thyroid Imaging Report and Data System (TI-RADS) proposed model, considering: vertical appearance, with antero-posterior diameter bigger than the transvers diameter, the so called taller than wide shape, irregular borders, intranodular inhomogeneity, marked hypoecogenicity, micro calcifications, the presence of suspect lymph nodes, and increased stiffness as suspicious for malignancy. The classification outcomes were compared with the pathology results, considered the gold standard diagnosis. The prevalence of cancer was 28.8%, with 13/45 cases having a clear diagnostic of cancer. Six cases were diagnosed with borderline follicular neoplasia, a category with unclear evolution, also considered as malignant in the analysis of the imaging results. In total, 16/19 cancer cases had increased stiffness on elastography. The cancer prevalence increased with TI-RADS category, being 25% in TI-RADS 4b category and 92.8% in TI-RADS 5 category. The AUROC (Area Under Receiver Operating Curve) of elastography alone, in differentiation of malignant thyroid nodules was 74.9%; the combination of elastographic and conventional ultrasound characteristics generated an even better AUROC, of 84.5%. The combined conventional ultrasound and elastography identified thyroid cancer in cases with intermediate cytology with a sensitivity of 89.5% with a specificity of 50%. High risk thyroid nodules, identified by combined high risk conventional ultrasound characteristics and increased stiffness, on strain elastography, are highly predictive for malignancy, in the intermediate cytology cases.
Identifiants
pubmed: 31540296
pii: diagnostics9030119
doi: 10.3390/diagnostics9030119
pmc: PMC6787586
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Romanian Government, Ministry of Communications and Information Society
ID : SMIS 45997/21.01.2014
Références
Eur J Endocrinol. 2013 Apr 15;168(5):649-55
pubmed: 23416955
Thyroid. 2017 Jul;27(7):983-984
pubmed: 28486057
Med Ultrason. 2015 Sep;17(3):327-32
pubmed: 26343081
Thyroid. 2010 Oct;20(10):1145-50
pubmed: 20860422
Langenbecks Arch Surg. 2010 Sep;395(7):865-71
pubmed: 20632029
Int J Health Sci (Qassim). 2012 Jun;6(2):159-73
pubmed: 23579269
AJR Am J Roentgenol. 2013 Jun;200(6):1317-26
pubmed: 23701071
J Clin Endocrinol Metab. 2012 Dec;97(12):4524-30
pubmed: 23066117
Thyroid. 2009 Apr;19(4):355-60
pubmed: 19355826
Cancer Cytopathol. 2012 Apr 25;120(2):117-25
pubmed: 21998003
Cancer Control. 2017 Oct-Dec;24(5):1073274817729231
pubmed: 28975825
Ultrasound Med Biol. 2012 Jul;38(7):1154-62
pubmed: 22542262
Exp Clin Endocrinol Diabetes. 2010 Oct;118(9):602-9
pubmed: 19856256
Int J Endocrinol. 2015;2015:908575
pubmed: 25954310
Int J Cancer. 1990 Nov 15;46(5):761-9
pubmed: 2228303
Diagn Cytopathol. 2002 Jan;26(1):41-4
pubmed: 11782086
J Clin Endocrinol Metab. 2007 Aug;92(8):2917-22
pubmed: 17535993
J Clin Endocrinol Metab. 2010 Dec;95(12):5274-80
pubmed: 20810572
Endocrine. 2015 May;49(1):175-83
pubmed: 25273318
J Zhejiang Univ Sci B. 2017 Jul;18(7):555-566
pubmed: 28681580
Ultrasound Med Biol. 2012 Feb;38(2):195-201
pubmed: 22178167
Radiographics. 2007 May-Jun;27(3):847-60; discussion 861-5
pubmed: 17495296
Endocr Pract. 2016 May;22(5):622-39
pubmed: 27167915
Clin Endocrinol (Oxf). 2007 Jan;66(1):13-20
pubmed: 17201796
Int J Prev Med. 2016 Mar 09;7:55
pubmed: 27076893
Clin Imaging. 2016 Sep-Oct;40(5):913-6
pubmed: 27183140
Thyroid. 2017 Nov;27(11):1341-1346
pubmed: 29091573
Acta Cytol. 2012;56(4):333-9
pubmed: 22846422
J Clin Endocrinol Metab. 2011 Nov;96(11):E1826-30
pubmed: 21865373
J Clin Imaging Sci. 2016 Dec 29;6:51
pubmed: 28123841
Diagn Interv Imaging. 2013 May;94(5):535-44
pubmed: 23623210
Korean J Pathol. 2014 Apr;48(2):133-9
pubmed: 24868226
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Cancer Cytopathol. 2010 Feb 25;118(1):17-23
pubmed: 20099311
Med Sci Monit. 2018 Sep 08;24:6273-6279
pubmed: 30194820
Gland Surg. 2018 Aug;7(Suppl 1):S8-S18
pubmed: 30175059
Ultrasound Med Biol. 2018 Mar;44(3):575-583
pubmed: 29305124